Interleukin 17A in atherosclerosis – Regulation and pathophysiologic effector function

Nordlohne, Johannes; Vietinghoff, Sibylle von

doi:10.1016/j.cyto.2017.06.016

Cited by 36 publications

(23 citation statements)

References 148 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…That is because macrophages play an important role by synthesizing many proinflammatory cytokines and producing mediators such as matrix metalloproteinases. These data obtained from recent studies suggest that IL-17 plays a role in many stages of atherosclerosis [36,37,38]. We detected an increased serum IL-17A and a positive correlation between serum IL-17A level and EAT, which may be interpreted as an indirect sign of increased coronary artery disease risk among a metabolic syndrome population.…”

Section: Discussionsupporting

confidence: 74%

The Relationship between Epicardial Adipose Tissue Thickness and Serum Interleukin-17a Level in Patients with Isolated Metabolic Syndrome

et al. 2019

View full text Add to dashboard Cite

In this study, it was aimed to investigate the relationship between the epicardial adipose tissue thickness (EATT) and serum IL-17A level insulin resistance in metabolic syndrome patients. This study enrolled a total of 160 subjects, of whom 80 were consecutive patients who applied to our outpatient clinic and were diagnosed with metabolic syndrome, and the other 80 were consecutive patients who were part of the control group with similar age and demographics in whom the metabolic syndrome was excluded. The metabolic syndrome diagnosis was made according to International Diabetes Federation (IDF)-2005 criteria. EATT was measured with transthoracic echocardiography (TTE) in the subjects. IL-17A serum levels were determined using the ELISA method. Fasting blood glucose, HDL, triglyceride, and fasting insulin levels were significantly higher in the metabolic syndrome group compared to the control group. In addition, the metabolic syndrome group had significantly higher high-sensitivity C-reactive protein (hs-CRP) and Homeostatic Model Assessment Insulin Resistance (HOMA-IR) levels than the control group. Similarly, serum IL-17A levels were significantly elevated in the metabolic syndrome group compared to the control group statistically (p < 0.001). As well, EATT was higher in the metabolic syndrome than the control group. Conclusion: By virtue of their proinflammatory properties, EATT and IL-17 may play an important role in the pathogenesis of the metabolic syndrome.

show abstract

Section: Discussionsupporting

confidence: 74%

The Relationship between Epicardial Adipose Tissue Thickness and Serum Interleukin-17a Level in Patients with Isolated Metabolic Syndrome

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Atherosclerosis and thromboembolic diseases are maladaptive chronic inflammatory diseases whose pathogenesis and progression are determined by an interaction between immunoinflammatory mechanisms, hemodynamic disturbances, activation of platelets and humoral coagulation factors, and lipid accumulation. The resulting ischemic diseases (e.g., myocardial infarction, cardiomyopathies or stroke) represent a prognosis-relevant comorbidity frequently associated with most inflammatory conditions, including those, like psoriasis, in which IL-17A appears to play an important role (91)(92)(93).…”

Section: The Role Of Inflammatory Cytokines In the Pathogenesis Of Atmentioning

confidence: 99%

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

et al. 2020

View full text Add to dashboard Cite

Interleukin 17A (IL-17A) is one of the currently known six members of the IL-17 cytokine family and is implicated in immune responses to infectious pathogens and in the pathogenesis of inflammatory autoimmune diseases like psoriasis. Psoriatic skin is characterized by high expression of IL-17A and IL-17F, which act on immune and non-immune cell types and strongly contribute to tissue inflammation. In psoriatic lesions, IL-17A, IL-17E, and IL-17F are involved in neutrophil accumulation, followed by the formation of epidermal micro abscesses. IL-17A together with other Th17 cytokines also upregulates the production of several chemokines that are implicated in psoriasis pathogenesis. IL17A-targeting antibodies show an impressive clinical efficacy in patients with psoriasis. Studies have reported an improvement of at least 75% as measured by the psoriasis area and severity index (PASI) in >80% of patients treated with anti-IL-17A therapy. Psoriasis skin manifestations, cardiovascular as well as metabolic disease in psoriasis appear to share pathogenic mechanisms evolving around IL-17A and its proinflammatory role. Thus, anti-IL-17A therapy not only improves skin manifestations of psoriasis, but also cardiovascular inflammation as well as metabolic factors and different domains of psoriatic arthritis (PsA) including peripheral arthritis, enthesitis, dactylitis, and axial involvement. This review summarizes the biological role of IL-17A, before reviewing currently available data on its role in the physiology and pathophysiology of the skin, as well as the cardiovascular and the metabolic system. In conclusion, clinical recommendations for patients with moderate to severe psoriasis based on the current available data are given.

show abstract

“…IL-17A responses vary depending on cell type and pathological conditions, exerting mainly proinflammatory responses [78][79][80][81][82]. In cultured cells, IL-17A regulates many proinflammatory factors, including chemokines, adhesion molecules, and cytokines [83][84][85][86].…”

Section: Il-17a As a Proinflammatory Mediator In Dnmentioning

confidence: 99%

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Lavoz

Rayego‐Mateos

Orejudo

et al. 2020

JCM

View full text Add to dashboard Cite

Chronic kidney disease has become a major medical issue in recent years due to its high prevalence worldwide, its association with premature mortality, and its social and economic implications. A number of patients gradually progress to end-stage renal disease (ESRD), requiring then dialysis and kidney transplantation. Currently, approximately 40% of patients with diabetes develop kidney disease, making it the most prevalent cause of ESRD. Thus, more effective therapies for diabetic nephropathy are needed. In preclinical studies of diabetes, anti-inflammatory therapeutic strategies have been used to protect the kidneys. Recent evidence supports that immune cells play an active role in the pathogenesis of diabetic nephropathy. Th17 immune cells and their effector cytokine IL-17A have recently emerged as promising targets in several clinical conditions, including renal diseases. Here, we review current knowledge regarding the involvement of Th17/IL-17A in the genesis of diabetic renal injury, as well as the rationale behind targeting IL-17A as an additional therapy in patients with diabetic nephropathy.

show abstract

Interleukin 17A in atherosclerosis – Regulation and pathophysiologic effector function

Cited by 36 publications

References 148 publications

The Relationship between Epicardial Adipose Tissue Thickness and Serum Interleukin-17a Level in Patients with Isolated Metabolic Syndrome

The Relationship between Epicardial Adipose Tissue Thickness and Serum Interleukin-17a Level in Patients with Isolated Metabolic Syndrome

IL-17A in Psoriasis and Beyond: Cardiovascular and Metabolic Implications

Could IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?

Contact Info

Product

Resources

About